Author Archives: truemeds

The AKT and Cancer signaling pathway is a pivotal regulator of cellular survival, proliferation, and metabolism, making it one of the most studied drivers of tumorigenesis. This blog post explores the origins, structure, and activation mechanisms of AKT isoforms (AKT1, AKT2, AKT3), their diverse oncogenic functions, and their contributions to key cancer hallmarks such as […]

Glycogen Synthase Kinase-3 (GSK-3) has emerged as a critical enzyme in the pathogenesis of neurodegenerative diseases, particularly Alzheimer’s disease (AD) and Parkinson’s disease (PD). This blog explores the dual role of GSK-3 in promoting tau hyperphosphorylation and amyloid-β production in AD, as well as its involvement in α-synuclein toxicity in PD. It reviews the therapeutic […]

Neosperidin dihydrochalcone (NHDC) is a high-intensity sweetener derived from citrus flavonoids, widely used in food, beverage, and pharmaceutical products. Recognized for its powerful sweetness—up to 1,500 times that of sucrose—NHDC is non-caloric, heat-stable, and effective at masking bitterness. It is produced through hydrogenation of neohesperidin, a compound found in bitter oranges. Approved in the EU […]

Organic Light Emitting Diodes (OLEDs) have revolutionized modern display and lighting technologies by enabling high-efficiency, flexible, and ultra-thin devices. This blog explores the fundamental OLED material components—emissive, transport, and injection layers—and how their performance drives device quality. It also highlights recent advances such as TADF emitters, printable OLEDs, and sustainable synthesis methods. Key applications include […]

The mammalian target of rapamycin (mTOR) pathway plays a central role in regulating protein synthesis, cellular metabolism, and growth. This blog post explores how mTOR integrates signals from nutrients, hormones, and energy status to control the initiation and elongation phases of translation, as well as ribosome biogenesis. Through its two complexes, mTORC1 and mTORC2, the […]

This article explores the most recent advances in Alopecia Areata (AA) research from 2023 to 2025, covering new treatment strategies, diagnostic tools, psychological impacts, and demographic-specific considerations. It highlights the role of JAK inhibitors such as baricitinib and tofacitinib in transforming care, as well as the use of dermoscopy and genetic insights for early diagnosis. […]

Tirzepatide (Mounjaro), marketed as Mounjaro, is a groundbreaking dual GIP and GLP-1 receptor agonist approved for the treatment of type 2 diabetes. Unlike traditional therapies, it offers a dual mechanism that improves glycemic control and promotes significant weight loss. Clinical trials have shown Tirzepatide to be more effective than leading GLP-1 agonists like semaglutide in […]

Anti-VEGF therapies have revolutionized cancer treatment by targeting tumor angiogenesis, yet their clinical effectiveness has often failed to meet expectations. While early-stage tumors in mouse models respond well to VEGF inhibition, human cancers typically display resistance due to vascular heterogeneity and the emergence of VEGF-independent blood vessels. This blog explores the limitations of current antiangiogenic […]